Jthiel

J-Pharma is a clinical-stage biopharmaceutical company based in Japan that focuses on the development of innovative drugs targeting nutrient transporters. The company's primary focus is on the L-type amino acid transporter 1 (LAT1), which is highly expressed in various cancer cells to support their rapid growth. Their lead candidate, nanvuranlat (JPH203), is a first-in-class small molecule inhibitor of LAT1 currently being evaluated in clinical trials for biliary tract cancer and other solid tumors. By inhibiting the uptake of essential amino acids, J-Pharma aims to provide a novel therapeutic approach for patients with treatment-refractory cancers.